Sharemaestro company-news research for Parabilis Medicines, Inc. Common Stock (PBLS), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.
NASDAQ
United States
Provisional evidence
Company news sentiment
Latest PBLS news and sentiment
Parabilis Medicines, Inc. Common Stock
Company headlines from the last 30 days, weighted by freshness, relevance, publisher quality and the strength of the wording. Price is shown separately.
Current company news
Early balanced news score
20 company-specific stories are available, but there are not yet enough fresh stories from separate publishers for a firm reading.
Observed headline tone38/100
→
Published 30-day score50/100
Latest source headline
Top Parabilis Medicines (PBLS) Competitors 2026
MarketBeat · 09 Oct 2026 02:35
Older, less relevant and less reliable stories count for less. Confidence is shown separately.
What supports the score
20 current stories are mapped specifically to PBLS.
What limits the score
Only 1 publisher currently contribute to the measured read.
The stories agree, but freshness-weighted evidence is only 0.002.
Confidence is 16/100, below the threshold for a firm score.
50/100
News scoreEarly balanced news score
16/100
Confidencethin evidence
100%/100
Company news20 company stories
96/100
Story agreement4/100 difference
News history
Daily score and story count over 30 days
17 Sep02 Oct16 Oct
News scoreStory count50 baseline
Confidence
How reliable the score is
Confidence uses the amount of news, separate publishers, direct company relevance, freshness and agreement. A high or low score is not automatically reliable.
Amount of evidence0
0.002 after freshness weightingSource breadth20
1 independent publishersCompany relevance100
share tied directly to this companyFreshness11
recency-weighted evidenceAgreement96
how closely stories agreePublisher mix0
less reliance on one publisherPrice and news history
Weekly price and news-score history
Company-specific news is present, but the evidence has not yet earned enough independent, fresh information weight for price confirmation to be treated as a firm signal.
18 completed price weeks18 comparable news-score weeks
One scoring method across the chart.Stored company headlines are recalculated at each weekly point with the current 30-day freshness weighting. Old published snapshots are left unchanged.
12 Jun11 Aug09 Oct
Weekly close, indexedSentiment score
WeekNews scoreCloseWeekly move
09 Oct 202648USD 27.48-9.2%
02 Oct 202646USD 30.28-2.9%
25 Sep 202648USD 31.2-25.2%
18 Sep 202650USD 41.73+13.2%
11 Sep 202650USD 36.88-8.8%
04 Sep 202650USD 40.42+3.3%
28 Aug 202651USD 39.11-0.6%
21 Aug 202651USD 39.36+6.2%
Provisional evidence
News subjects
What is shaping the score
Market update4917 stories · 85%
Analyst action341 stories · 5%
Earnings501 stories · 5%
Balance sheet501 stories · 5%
Source mix
Where the evidence comes from
MarketBeat4811 stories · 55%
Simply Wall Street502 stories · 10%
marketscreener.com502 stories · 10%
Stock Titan501 stories · 5%
mexc.co501 stories · 5%
www.marketscreener.com501 stories · 5%
mexc.com501 stories · 5%
Recurring subjects
Subjects appearing most often
Life Sciences10Financial Markets9Earnings6IPO2Finance2
Earlier readings
How the score has changed
Past and present use the same method.Each point recalculates the previous 30 days of stored company headlines with today's scoring rules. The original stored snapshots remain unchanged.
12 Jun50 neutral16 Oct 14:43
ConstructiveBalanced or withheldCautious
Changes in the stored score
Scores are rebuilt from stored headlines with the current 30-day method. Days with no change are collapsed.
| Observed | Score | Move | Confidence | Stories | Status |
|---|---|---|---|---|---|
| 16 Oct 14:43 | 49 | +1 | 18/100 (-4) | 19 (-3) | Provisional |
| 09 Oct 23:59 | 48 | +0 | 22/100 (-1) | 22 (0) | Provisional |
| 08 Oct 23:59 | 48 | +2 | 23/100 (-10) | 22 (0) | Provisional |
| 02 Oct 23:59 | 46 | -3 | 33/100 (+16) | 22 (-1) | Provisional |
| 30 Sep 23:59 | 49 | +0 | 17/100 (-2) | 23 (0) | Provisional |
| 28 Sep 23:59 | 49 | +2 | 19/100 (-10) | 23 (-11) | Provisional |
| 22 Sep 23:59 | 47 | -3 | 29/100 (+13) | 34 (+2) | Provisional |
| 21 Sep 23:59 | 50 | +0 | 16/100 (0) | 32 (+1) | Provisional |
Evidence behind the direction
What drives this reading?
Shares of weighted directional evidence in 20 retained current headlines. These weights already account for freshness, relevance and publisher limits; they are not additive points of the published score.
Which subjects lean each way
A subject can carry both supportive and cautious news.
SubjectCautious ← 0 → Constructive
Market update1 story
54.3%0.0%
Analyst action1 story
45.7%0.0%
Each side uses the same scale: 0–54.3% of the retained directional evidence.
Where the influence comes from
100.0%largest publisher shareA concentrated reading can depend heavily on one publisher.
Publisher groups follow the scoring rules. Company disclosures share one group; syndicated stories are consolidated before weighting.
Source headlines
The news behind the score
Only company-specific stories enter this score. The latest 30 days are shown newest first, with newer stories weighted more heavily and duplicate coverage combined.
—Unscored
Market updateNot used in direction
Top Parabilis Medicines (PBLS) Competitors 2026
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 09 Oct 2026 02:35
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 7.5d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
—Unscored
Market updateNot used in direction
Parabilis Medicines (NASDAQ:PBLS) Stock Price Down 7.6% - What's Next?
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 08 Oct 2026 16:18
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 7.9d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
42/100 tone
Parabilis Medicines (NASDAQ:PBLS) saw its shares drop by 5.2% to $28.85, with trading volume significantly lower than average. Despite the recent decline and a substantial EPS miss in their latest quarterly report, analysts maintain a "Moderate Buy" consensus rating with an average price …
54.3% of directional evidence
Low story strength
Scoring detailsDirect company coverage
Parabilis Medicines (NASDAQ:PBLS) saw its shares drop by 5.2% to $28.85, with trading volume significantly lower than average. Despite the recent decline and a substantial EPS miss in their latest quarterly report, analysts maintain a "Moderate Buy" consensus rating with an average price target of $41.67. The company missed analyst consensus estimates for EPS by a large margin and reported minimal revenue for the quarter.
- Published
- 02 Oct 2026 17:24
- News subject
- Market update
- Why this score
- Negative market reaction, Large negative market reaction
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Low · 35/100
- 30-day weight
- 54.3% of directional evidence · 13.9d old
- Text assessed
- Available headline and article text
- Duplicates
- 3 consolidated
EarningsFinancial MarketsLife Sciences
—Unscored
Market updateNot used in direction
Top Parabilis Medicines (PBLS) Competitors 2026
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 30 Sep 2026 22:11
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 15.7d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
—Unscored
Market updateNot used in direction
Parabilis Medicines (NASDAQ:PBLS) Shares Up 6% - What's Next?
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 28 Sep 2026 20:04
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 17.8d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
—Unscored
Market updateNot used in direction
Parabilis Medicines (PBLS) Stock Price, News & Analysis
Parabilis Medicines (PBLS) stock closed at $31.91 on September 29, 2026, marking an 18.4% decline over the past month, yet it maintains a market capitalization of $3.9 billion. The company has recently been active with SEC filings, including updates on tumor trial data and leadership chan…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Parabilis Medicines (PBLS) stock closed at $31.91 on September 29, 2026, marking an 18.4% decline over the past month, yet it maintains a market capitalization of $3.9 billion. The company has recently been active with SEC filings, including updates on tumor trial data and leadership changes, and has seen significant insider buying activity. Short interest in PBLS has increased by 445.7% since June 2026, and its days to cover stands at 13.3 days.
- Published
- 28 Sep 2026 12:24
- News subject
- Market update
- Why this score
- Negative financial language
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 18.1d old
- Text assessed
- Available headline and article text
- Duplicates
- 2 consolidated
EarningsFinanceFinancial MarketsIPOLife Sciences
—Unscored
Market updateNot used in direction
PBLS Price Today: Parabilis Medicines, Inc. Stock Price, Quote & Chart | MEXC
This article provides a detailed overview of Parabilis Medicines, Inc. (PBLS) stock performance and company information. As of the last update, PBLS is trading at $31.20, having experienced a 23.68% decline over the past seven days, and has a market capitalization of $4.01 billion. The co…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
This article provides a detailed overview of Parabilis Medicines, Inc. (PBLS) stock performance and company information. As of the last update, PBLS is trading at $31.20, having experienced a 23.68% decline over the past seven days, and has a market capitalization of $4.01 billion. The company operates in the pharmaceutical preparations sector, focusing on developing stabilized helical peptide therapeutics, with its flagship product candidate, zolucatetide, targeting cancer pathways.
- Published
- 23 Sep 2026 01:50
- News subject
- Market update
- Why this score
- Negative financial language
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 23.5d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
Financial MarketsLife Sciences
—Unscored
Market updateNot used in direction
Parabilis Medicines (NasdaqGS:PBLS) Stock Price
This article provides a financial overview of Parabilis Medicines (NasdaqGS:PBLS), highlighting its stock price performance, fair value, and key financial details. It emphasizes the company's helical peptide platform and Regeneron alliance as drivers for oncology upside, despite its curre…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
This article provides a financial overview of Parabilis Medicines (NasdaqGS:PBLS), highlighting its stock price performance, fair value, and key financial details. It emphasizes the company's helical peptide platform and Regeneron alliance as drivers for oncology upside, despite its current undervaluation. Recent news includes executive changes and a detailed biography of a new board appointee with extensive oncology drug development experience.
- Published
- 22 Sep 2026 18:54
- News subject
- Market update
- Why this score
- Positive financial language
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 23.8d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
EarningsFinancial MarketsLife Sciences
34/100 tone
Parabilis Medicines (NASDAQ:PBLS) saw its stock price drop by 6.3% during mid-day trading, reaching $39.10 on significantly lower trading volume. This decline follows a substantial quarterly earnings miss, where the company reported a $2.32 loss per share against an expected $0.16 loss. D…
45.7% of directional evidence
Medium story strength
Scoring detailsDirect company coverage
Parabilis Medicines (NASDAQ:PBLS) saw its stock price drop by 6.3% during mid-day trading, reaching $39.10 on significantly lower trading volume. This decline follows a substantial quarterly earnings miss, where the company reported a $2.32 loss per share against an expected $0.16 loss. Despite the recent dip and earnings miss, analysts generally maintain a "Moderate Buy" rating for PBLS with an average price target of $41.67.
- Published
- 22 Sep 2026 00:39
- News subject
- Analyst action
- Why this score
- Missed expectations, Negative market reaction, Large negative market reaction
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 45/100
- 30-day weight
- 45.7% of directional evidence · 24.6d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
EarningsFinanceFinancial MarketsLife Sciences
—Unscored
Market updateNot used in direction
Top Parabilis Medicines (PBLS) Competitors 2026
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 21 Sep 2026 23:37
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 24.6d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
—Unscored
Market updateNot used in direction
Parabilis Medicines (Nasdaq:PBLS) - Stock Analysis
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 21 Sep 2026 07:00
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 25.3d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
—Unscored
EarningsNot used in direction
Parabilis Medicines, Inc. (NASDAQ:PBLS) Given Average Recommendation of "Moderate Buy" by Analysts
Parabilis Medicines, Inc. (NASDAQ:PBLS) has received an average "Moderate Buy" recommendation from analysts, with an average 12-month price target of $41.67. Despite the positive analyst sentiment, including four buy and one strong buy rating, the company recently reported a significant e…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Parabilis Medicines, Inc. (NASDAQ:PBLS) has received an average "Moderate Buy" recommendation from analysts, with an average 12-month price target of $41.67. Despite the positive analyst sentiment, including four buy and one strong buy rating, the company recently reported a significant earnings miss and its shares are trading near their 52-week high. Institutional investors have increased their stakes in PBLS during the second quarter.
- Published
- 20 Sep 2026 08:19
- News subject
- Earnings
- Why this score
- Missed expectations, Buy Rating
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 26.3d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
EarningsFinancial MarketsLife Sciences
—Unscored
Market updateNot used in direction
Parabilis Medicines, Inc.(NasdaqGS:PBLS) added to Russell Small Cap Comp Growth Index
Parabilis Medicines, Inc. (NasdaqGS:PBLS) has been added to the Russell Small Cap Comp Growth Index, effective September 17, 2026. This inclusion is part of a series of recent additions to various Russell indices, including the Russell 3000 Value, Russell 2000 Value, and Russell 3000 Grow…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Parabilis Medicines, Inc. (NasdaqGS:PBLS) has been added to the Russell Small Cap Comp Growth Index, effective September 17, 2026. This inclusion is part of a series of recent additions to various Russell indices, including the Russell 3000 Value, Russell 2000 Value, and Russell 3000 Growth Indices. The company is a clinical-stage biopharmaceutical firm focused on developing transformative medicines for undruggable protein targets using its proprietary Helicon platform.
- Published
- 18 Sep 2026 00:39
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 28.6d old
- Text assessed
- Available headline and article text
- Duplicates
- 2 consolidated
Financial MarketsLife Sciences
—Unscored
Market updateNot used in direction
Parabilis Medicines, Inc.(NasdaqGS: PBLS) added to Russell 2000 Value Index
Parabilis Medicines, Inc. (NasdaqGS: PBLS) has been added to the Russell 2000 Value Index, among several other Russell indices. The company, a clinical-stage biopharmaceutical firm, focuses on developing transformative medicines using its proprietary Helicons platform. Its lead product ca…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Parabilis Medicines, Inc. (NasdaqGS: PBLS) has been added to the Russell 2000 Value Index, among several other Russell indices. The company, a clinical-stage biopharmaceutical firm, focuses on developing transformative medicines using its proprietary Helicons platform. Its lead product candidate, zolucatetide, is designed to inhibit the b-catenin:TCF interaction.
- Published
- 18 Sep 2026 00:39
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 28.6d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
Financial MarketsLife Sciences
—Unscored
Market updateNot used in direction
Parabilis Medicines, Inc.(NasdaqGS: PBLS) added to Russell 3000 Value Benchmark
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 17 Sep 2026 22:00
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 28.7d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
—Unscored
Market updateNot used in direction
48,484 Shares in Parabilis Medicines, Inc. $PBLS Acquired by Squarepoint Ops LLC
Squarepoint Ops LLC recently acquired 48,484 shares of Parabilis Medicines (NASDAQ:PBLS) valued at approximately $1.33 million. Other institutional investors like ICONIQ Capital and General Catalyst also made significant investments. Analysts maintain a "Moderate Buy" rating with an avera…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Squarepoint Ops LLC recently acquired 48,484 shares of Parabilis Medicines (NASDAQ:PBLS) valued at approximately $1.33 million. Other institutional investors like ICONIQ Capital and General Catalyst also made significant investments. Analysts maintain a "Moderate Buy" rating with an average price target of $41.67, despite the company reporting a wider-than-expected quarterly loss.
- Published
- 17 Sep 2026 19:53
- News subject
- Market update
- Why this score
- Institutional or insider buying
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 28.8d old
- Text assessed
- Available headline and article text
- Duplicates
- 2 consolidated
EarningsFinancial MarketsLife Sciences
—Unscored
Market updateNot used in direction
PBLS Price Today: Parabilis Medicines, Inc. Stock Price, Quote & Chart | MEXC
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 17 Sep 2026 09:57
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 29.2d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
—Unscored
Market updateNot used in direction
Parabilis Medicines (NASDAQ:PBLS) Hits New 52-Week High - Time to Buy?
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 17 Sep 2026 07:00
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 29.3d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
—Unscored
Balance sheetNot used in direction
Parabilis at Morgan Stanley conference: broad bet on beta-catenin
Parabilis Therapeutics outlined its strategy at the Morgan Stanley 24th Annual Global Healthcare Conference, focusing on its Helicon platform and lead drug zolucatetide. The company presented promising early clinical data for zolucatetide in desmoid tumors, familial adenomatous polyposis …
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Parabilis Therapeutics outlined its strategy at the Morgan Stanley 24th Annual Global Healthcare Conference, focusing on its Helicon platform and lead drug zolucatetide. The company presented promising early clinical data for zolucatetide in desmoid tumors, familial adenomatous polyposis (FAP), and adenomatoid cystic pituitary (ACP) tumors, highlighting a broad approach to targeting beta-catenin-driven diseases. With $1.1 billion in cash, Parabilis plans a Phase III desmoid study in early 2027 and is advancing other pipeline programs and partnerships.
- Published
- 16 Sep 2026 20:01
- News subject
- Balance sheet
- Why this score
- No clear directional signal in the available text
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 29.8d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
IPOLife Sciences
—Unscored
Market updateNot used in direction
Parabilis Medicines (NASDAQ:PBLS) Trading Up 6% - Still a Buy?
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 16 Sep 2026 16:17
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 29.9d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
Earlier company news
PBLS news archive
Stored newest first for historical research. It starts after the newest three pages above and then continues through older news. Each archive page is loaded only when it is opened.
Older news is kept in the archive
There are 56 older PBLS headlines. Open one page at a time when you need them.
Open older archiveProvider matches checked
Provider mentions not used in the score
A news provider linked these stories to PBLS, but the headline and available text are not mainly about Parabilis Medicines, Inc. Common Stock. They are kept here for transparency and do not affect the score, confidence, history or wider market totals.
Provider mentions are kept separate
Open the list to see which provider matches were checked and left out of PBLS sentiment.
Open provider mentionsHow the page works
How to read the score
It describes the weighted balance of qualifying headlines. A score of 50 can mean balanced news or that there is not enough evidence; the status label explains which.
Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme. This is a rule-based evidence measure, not a calibrated probability.
Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.
It measures news already published. It is not a forecast, recommendation or price target.